@Article{dbt_mods_00060380,
  author = 	{Sch{\"o}nherr, Jacqueline
		and Seifert, Philipp
		and G{\"u}hne, Falk
		and Winkens, Thomas
		and Rauchfu{\ss}, Falk
		and Settmacher, Utz
		and Freesmeyer, Martin
		and Drescher, Robert},
  editor = 	{Wong, David},
  title = 	{Transarterial Radioembolization (TARE) in Patients with Hepatocellular Carcinoma: A Comparison of Palliative with Bridging-to-Transplant Concepts},
  journal = 	{Cancers},
  year = 	{2024},
  month = 	{Jan},
  day = 	{04},
  publisher = 	{MDPI},
  address = 	{Basel},
  volume = 	{16},
  number = 	{1},
  keywords = 	{liver carcinoma; hepatocellular carcinoma; radioembolization; liver transplantation; bridging therapies},
  abstract = 	{We investigated transarterial radioembolization (TARE) as a palliative measure and bridging-to-transplant therapy in hepatocellular carcinoma (HCC) patients. A total of 167 patients (50 bridging, 117 palliative) with 245 TARE procedures were assessed. Fourteen patients underwent subsequent liver transplantation (LT). Patients undergoing LT exhibited significantly prolonged progression-free survival (PFS) compared to those with bridging-without-transplant ( p = 0.033). No significant differences were observed between patients with bridging-without-transplant and palliative cases ( p = 0.116). Median overall survival (OS) post-TARE was 16.6 months, with estimated OS rates at 6/12 months of 82.0{\%}/60.5{\%}, respectively. Patients who underwent LT demonstrated statistically significantly longer OS compared to those with bridging-without-transplant ( p = 0.001). No marked outcome distinctions were found between bridging-without-transplant and palliative groups. The findings underscored the superiority of LT over alternative treatments. TARE served as an important component in non-LT scenarios, allowing for subsequent therapeutic options. The study reflected the highly variable and complex situations of patients with HCC, emphasizing the need for further investigations to define an optimal multimodal approach.},
  note = 	{Zweitver{\"o}ffentlichung},
  issn = 	{2072-6694},
  doi = 	{10.3390/cancers16010235},
  url = 	{https://www.db-thueringen.de/receive/dbt_mods_00060380},
  url = 	{http://uri.gbv.de/document/gvk:ppn:614095670},
  url = 	{https://doi.org/10.3390/cancers16010235},
  file = 	{:https://www.db-thueringen.de/servlets/MCRFileNodeServlet/dbt_derivate_00062973/cancers-16-00235.pdf:PDF},
  language = 	{en}
}